Christopher Scrase - Concepedia

Author

Christopher Scrase

Also Known As

Andrew Wilson, C D Scrase, C Scrase, C. D. Scrase, C. Scrase, C.D. Scrase, Chris Rose, Christopher D Scrase, Christopher D. Scrase, Christopher Scrase

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Ipswich Hospital Institute of Cancer Research Clatterbridge Cancer Centre NHS Foundation Trust Royal Marsden NHS Foundation Trust Cardiff University

About

Christopher Scrase is an author at Ipswich Hospital specializing in radiation oncology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	2.4K
2	Health Sciences	11	11	1.5K
3	Engineering	1	1	35
4	Public Health	1	1	599
5	Biomedical Engineering	1	1	35

Christopher Scrase

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Christopher M. Nutting, James P. Morden, Kevin J. Harrington, The Lancet Oncology	2011	1.7K
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial David P. Dearnaley, Isabel Syndikus, Helen Mossop, The Lancet Oncology	2016	1.3K
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial David P. Dearnaley, Matthew R. Sydes, John D. Graham, The Lancet Oncology Radiation TherapyMedicineMrc Rt01Radiation Therapy PlanningComparative Planning	2007	904
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, The Lancet Oncology Primary Tumour SubtypeEpidemiologyCancer EpidemiologyCovid-19 PrevalenceMedicine	2020	599
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial David P. Dearnaley, Gordana Jovic, Isabel Syndikus, The Lancet Oncology	2014	453
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group Philip Poortmans, Alberto Bossi, Katia Vandeputte, Radiotherapy and Oncology Target Volume DefinitionRadiation MedicineRadiation TherapyMedicineRadiation Therapy Planning	2007	306
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial David P. Dearnaley, Isabel Syndikus, G. Sumo, The Lancet Oncology	2011	304
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991 M. Bolla, P. Maingon, C. Carrié, Journal of Clinical Oncology	2016	211
Guidelines for primary radiotherapy of patients with prostate cancer Dirk Boehmer, P. Maingon, Philip Poortmans, Radiotherapy and Oncology Radiation MedicineUrologyMedicineBrachytherapyProstatic Disease	2006	151
Clinical and patient‐reported outcomes of <scp>SPARE</scp> – a randomised feasibility study of selective bladder preservation versus radical cystectomy Robert Huddart, Alison Birtle, Lauren Maynard, British Journal of Urology	2017	151

Page 1